BioNTech SE
BNTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The $22.13B market capitalization puts BNTX squarely in large-cap range for its industry. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Market Cap
$22.13B
Beta
1.25
P/E (TTM)
—
P/E (Fwd)
-16.30
EPS (TTM)
$-7.69
EPS (Fwd)
$-5.41
ROE
-9.3%
ROA
-5.4%
Cash
$13.46B
Total Debt
$316.1M
Free CF
-$249.6M
52W Change
-16.6%
Annual Financials
Cash vs Debt
Where BNTX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, BNTX finished 7.59% below its 150-day moving average ($94.91) and 10.21% below its 200-day moving average ($97.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BNTX overbought or oversold?
At the October 19, 2026 close, BNTX's RSI(14) was 28.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $13.46B in cash comfortably exceeding the $316.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$249.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -9.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $17.31B (2022) to $2.87B (2025), a 83% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioNTech SE's trajectory.